Abstract
Juvenile idiopathic arthritis is the most common pediatric rheumatic condition. Advances in identification of cytokines, inflammatory networks and genes involved in the pathogenesis of the disease may lead us towards a more personalized approach to treatment and a biological classification of juvenile idiopathic arthritis. Identification of biomarkers for disease activity, response to treatment and use of ultrasound may improve the definition of inactive disease and remission. New treatment targets and use of comparative effectiveness research can facilitate protocolized treatment that is specific to each child's disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
